Table 3.

Cutoffs for GALAD score at the maximum sensitivity and specificity in the ROC curve in the EDRN multicenter cohort

SubgroupsGALAD cutoffSensitivity (95% CI)Specificity (95% CI)GALAD cutoffSensitivity (95% CI)Specificity (95% CI)AUC (95% CI)
Overall (233 HCCs, 412 controls)−0.1776% (70%–82%)86% (82%–89%)−0.6379% (74%–84%)79% (75%–83%)0.88 (0.85–0.91)
Etiology subgroup
 Alcohol (24 HCCs, 48 controls)0.8271% (49%–87%)92% (80%–98%)−0.6383% (67%–96%)67% (54%–79%)0.89 (0.81–0.97)
 HBV (46 HCCs, 23 controls)−1.2583% (69%–92%)100% (85%–100%)−0.6372% (59%–85%)100% (100%–100%)0.94 (0.88–0.99)
 HCV (122 HCCs, 240 controls)−0.1779% (70%–85%)85% (80%–89%)−0.6382% (75%–88%)77% (72%–82%)0.89 (0.86–0.92)
 Nonviral/alcohola (41 HCCs, 101 controls)−0.1678% (62%–89%)93% (86%–97%)−0.6378% (63%–90%)85% (78%–92%)0.88 (0.81–0.96)
AFP
 AFP <20 (95 HCCs, 360 controls)−1.2777% (67%–85%)73% (68%–78%)−0.6355% (44%–64%)85% (81%–88%)0.80 (0.75–0.85)
 AFP ≥ 20 (137 HCCs, 48 controls)2.3972% (63%–79%)90% (77%–97%)−0.6396% (93%–99%)38% (25%–52%)0.87 (0.81–0.93)
Tumor stage
 Very early (BCLC 0; 10 HCCs, 412 controls)−0.1680% (44%–97%)86% (83%–89%)−0.6380% (50%–100%)79% (75%–83%)0.86 (0.76–0.96)
  • aNonviral/alcohol refers to all other etiologies combined other than alcohol, HBV, and HCV.